Edenred: cash machine versus regulators
Will commercial growth outrun lower fees and faster merchant reimbursement? Research checked 9 November 2026. Ordinary EDEN.PAR share in EUR; ISIN FR0010908533. Dated 6 November provider close €24.60, not live Monday. Current public weighted Strong Buy both horizons; separate Strong Buy & Keep for Dividends.
H1 total revenue €1,473m; parent net profit €214m; EBITDA €616m. EBITDA margin 41.82% on total revenue versus 45.07%. Company FCF bridge, €m: 432 − 553 + 66 − 99 = −154. Statutory operating cash differs because of a separately classified €8m non-recurring cash cost. June net debt €1,764m was lower than the prior June but higher than December. Customer money and restricted cash are not freely distributable.
Fixed 18 September 2027/2031 weighted price endpoints €33.02/€52.74 imply cumulative price returns +34.21%/+114.41% using unrounded targets. Flat future annual €1.33 cash: one/five assumed payments €1.33/€6.65, giving gross cash-inclusive +39.62%/+141.44% before tax/fees without reinvestment. The already-paid June dividend is excluded; future payments are not declared. Platform net-yield/reinvestment returns are a separate method.
Q3 operating revenue €667m: flat reported, −1.20% like for like, +6.60% intrinsic after also excluding Italian/Brazilian regulatory effects. Intrinsic is a revenue measure, not volume. Organic EBITDA decline guidance remains 7–10%; the small euro-range change reflected transaction scope. Management's 2027/2028 growth and annual conversion objectives remain conditional. All 20 original weighted quarter steps are positive, not a promised stock path.
Upside: profitable fleet growth, cross-selling or a genuinely financed takeover. Downside: further fee restrictions, shorter float and adverse legal outcomes. Exploratory approaches are not a bid or floor; investigation is not guilt. Fourteen correlated AI contributions, separate July comparisons and newer primary evidence; upstream manual-display QA remains open.
Research and primary evidence
Three related episodes
EP 31 | Adyen Stock Analysis: Will It Make Investors Rich? — Payment volume and settlement balances differ from shareholder revenue and free cash; merchant acquiring differs from employee benefits. Listen and read · ▶Watch on YouTube
PayPal: Cash Machine or Value Trap? | EP 011 | AI Investment Edge — Cash definitions, customer obligations and cash after investment; no stale valuation comparison. Listen and read · ▶Watch on YouTube
EP 39 | PepsiCo Stock Analysis: Will the Cash Recovery Last? — Cash recovery versus headline growth; consumer pricing and costs differ from benefit fee regulation. Listen and read · ▶Watch on YouTube
Last stock: Nu Holdings Episode 41 (▶YouTube).
For the bigger picture, visit iPulse AI to explore our complete rankings of covered assets, discover the Strongest Buys, and see the research behind the ratings, all in one place. Primary research conducted through the iPulse AI platform by Future Edge Group. Like, comment and subscribe. We are publishing a new podcast every Monday through Friday. Stay tuned for the next podcast on TransMedics.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit